Bevacizumab NEW
| Price | $129 | $212 | $396 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-21 |
Product Details
| Product Name: Bevacizumab | CAS No.: 216974-75-3 |
| Purity: 98.00% | Supply Ability: 10g |
| Release date: 2026/05/21 |
Product Introduction
Bioactivity
| Name | Bevacizumab |
| Description | Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A. |
| Cell Research | Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium supplemented with 5% heat-inactivated FCS, 100 U/mL Penicillin, 100 U/mL Streptomycin, and endothelial cell growth supplement. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2]. |
| Kinase Assay | The binding kinetics of Bevacizumab or FD006 to VEGF is measured using Bio-Layer Inter-Ferometry on Octet RED. The assay is conducted at 30°C in PBS buffer. Sensor tips are pre-wet for 15 mins in buffer immediately prior to use, and the microplates are filled with 200 μL per well of diluted samples (VEGF) or buffer and agitated at 1000 rpm. The anti-human IgG biosensor are pre-saturated with Bevacizumab or FD006 (10 μg/mL) and washed in buffer for 120 seconds, and then transferred to VEGF at concentrations of 10 μg/mL, 3 μg/mL and 1 μg/mL. The VEGF association and dissociation rates are measured for 5mins and 10mins, respectively. The Kinetics parameters (Kon and Koff) and affinities (KD) are calculated from a non-linear global fit using the Octet analysis software. Multiple independent measurements are performed[2]. |
| In vitro | METHODS: Human lung cancer cells A549 were treated with Bevacizumab (1-25 μM) for 12-72 h. Cell proliferation was detected by CCK-8 assay. RESULTS: Bevacizumab treatment of A549 cells for 12 h showed mild inhibition of cell proliferation, but after 24 h showed significant induction of apoptosis in a dose-dependent manner. [1] METHODS: Human tumor cells AGS, Caco2 and HepG2/C3A were treated with Bevacizumab (5 ng/mL-100 μg/mL) for 48 h. Telomerase expression and activity were measured by semi-quantitative RT-PCR. RESULTS: Bevacizumab (5 ng/mL) increased hTERT mRNA levels in AGS by 35.2%, Caco2 by 62.0%, and HepG2/C3A by 21.8%. In contrast, Bevacizumab (100 μg/mL) increased hTERT mRNA levels in AGS by 42.3%, Caco2 by 94.1%, and HepG2/C3A by 52.5%. Thus, Bevacizumab significantly increased hTERT mRNA levels and telomerase activity in AGS, Caco2 and HepG2/C3A. [2] |
| In vivo | METHODS: To investigate antitumor activity, Bevacizumab (2-5 mg/kg) was injected intraperitoneally into nude mice bearing xenografts of human osteosarcoma cells 143B-RFP twice a week for 43 days. RESULTS: Bevacizumab exhibited potent anti-angiogenic activity in a nude mouse model of experimental osteosarcoma without affecting the incidence of lung metastases. [3] |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | VEGFR | Bevacizumab |
| Inhibitors Related | Ribociclib | Regorafenib monohydrate | Sorafenib | glycine | Nintedanib esylate | Regorafenib | Ethyl cinnamate | Chloramphenicol | Thymoquinone | Lenvatinib | Pazopanib | Albendazole |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-10 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-10 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
|
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY